Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Non-Current Assets: 2021-2024

Historic Non-Current Assets for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $16.9 million.

  • ARS Pharmaceuticals' Non-Current Assets rose 285.16% to $33.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.9 million, marking a year-over-year increase of 285.16%. This contributed to the annual value of $16.9 million for FY2024, which is 1053.08% up from last year.
  • According to the latest figures from FY2024, ARS Pharmaceuticals' Non-Current Assets is $16.9 million, which was up 1,053.08% from $1.5 million recorded in FY2023.
  • ARS Pharmaceuticals' Non-Current Assets' 5-year high stood at $16.9 million during FY2024, with a 5-year trough of $716,000 in FY2021.
  • Moreover, its 3-year median value for Non-Current Assets was $3.7 million (2022), whereas its average is $7.4 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first tumbled by 60.86% in 2023, then spiked by 1,053.08% in 2024.
  • Over the past 4 years, ARS Pharmaceuticals' Non-Current Assets (Yearly) stood at $716,000 in 2021, then soared by 421.65% to $3.7 million in 2022, then tumbled by 60.86% to $1.5 million in 2023, then spiked by 1,053.08% to $16.9 million in 2024.